1. Cancer Metastasis: New Perspectives of Old Problem
1.1 Overview to Cancer
1.1.1 Process of Metastatic Cancer
1.1.2 Risk Factors Involved for the Metastasis of Cancer
1.2 Genes Involved in Metastasis of Cancer
2. Metastatic Lung Cancer
2.1 Introduction
2.2 Management Approaches for Metastatic Lung Cancer
2.3 Advancements in the Treatment of Metastatic Lung Cancer
3. Metastatic Bone Cancer
3.1 Introduction
3.2 Management Approaches of Metastatic Bone Cancer
4. Metastatic Breast Cancer
4.1 Overview
4.2 Management Methods for Metastatic Breast Cancer
4.3 Ongoing Advancements in Metastatic Breast Cancer Treatment
5. Metastatic Liver Cancer
5.1 Introduction
5.2 Management Approaches of Metastatic Liver Cancer
6. Metastatic Brain Cancer
6.1 Outline
6.2 Management Methods for Metastatic Brain Tumor
6.3 Developments in Metastatic Brain Tumors
7. Metastatic Prostate Cancer
7.1 Introduction
7.2 Management of Metastatic Prostate Cancer
7.3 Recent Advances in Metastatic Prostate Cancer Treatment
8. Process of Metastasis in Other Different Types of Cancers
8.1 Ovarian Cancer
8.2 Thyroid Cancer
8.3 Pancreatic Cancer
9. Patent, Availability, Price & Dosage Analysis of Metastatic Lung Cancer Therapeutics
9.1 Targeted Drugs
9.1.1 Erlotinib (Tarceva)
9.1.2 Gefitinib (Iressa)
9.1.3 Afatinib (Gilotrif)
9.2 Chemotherapy Drugs
9.2.1 Cisplatin
9.2.2 Topotecan (Hycamtin)
9.2.3 Pemetrexed (Alimta)
10. Patent, Availability, Price & Dosage Analysis of Metastatic Bone Cancer Therapeutics
10.1 Denosumab
10.2 Radium 223
10.3 Zoledronic acid
11. Patent, Availability, Price & Dosage Analysis of Metastatic Breast Cancer Therapeutics
11.1 Chemotherapy Drugs
11.1.1 Capecitabine
11.1.2 Eribulin (Halaven)
11.1.3 Ixabepilone (Ixempra)
11.2 Targeted Therapy Drugs
11.2.1 Avastin (Bevacizumab)
11.2.2 Herceptin
12. Patent, Availability, Price & Dosage Analysis of Metastatic Liver Cancer Therapeutics
12.1 Sorafenib (Nexavar)
12.2 Melphalan (Alkeran)
13. Patent, Availability, Price & Dosage Analysis of Metastatic Prostate Cancer Therapeutics
13.1 Taxotere (Docetaxel)
13.2 Jevtana (Cabazitaxel)
13.3 Provenge (Sipuleucel-T)
14. Market Analysis of Metastatic Cancer
14.1 Current Market Growth of Metastatic Cancer by its Types
14.2 Global Sales of Metastatic Cancers Drugs
15. Market Dynamics of Metastatic Cancer
15.1 Favorable Parameters
15.2 Challenges
16. Future Perspective of Metastatic Cancer Market17. Global Cancer Metastases Clinical Pipeline Overview18. Global Cancer Metastases Clinical Pipeline by Company, Indication & Phase
18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-III
18.9 Preregistration
19. Marketed Cancer Metastases Drugs Clinical Insight
19.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)
19.2 Radium-223 Chloride (Alpharadin & Xofigo)
19.3 Zoledronic Acid (Aclasta, Reclast & Zometa)
19.4 Pamidronic Acid (Aminomux, Aredia & Panorin)
19.5 Clodronic Acid (Ascredar, Bonefos, Bonephos, Clasteon, Clastoban, Climaclod, Clodeosten, Clodron, Clodron beta, Clody, Difosfonal, Dolkin, Hemocalcin, Lodronat, Loron, Lytos, Mebonat, Moticlod, Nikclod, Ossiten, Ostac, Osteonorm, Osteostab & Sindronat)
19.6 Ibandronic Acid (Bondronat, Boniva & Bonviva)
19.7 Thiotepa (Tepadina & Thioplex)
19.8 Miltefosine (Impavido, Miltefosin & Miltex)
19.9 Irinotecan-Eluting Beads (DEBIRI & PARAGON Bead)
19.10 Melphalan Drug Delivery System (Delcath Hepatic CHEMOSAT Delivery System for Melphalan & Melblez Kit)
19.11 Ethiodised Oil (Lipiodol)
19.12 Zoledronic Acid - Sagent Pharmaceuticals
19.13 Tc 99m Besilesomab (Scintimun)
19.14 Mopidamol (Rapenton)
20. Competitive Landscape
20.1 Allergan
20.2 Amgen
20.3 Biocompatibles International
20.4 Boehringer Ingelheim Pharma
20.5 Celsion Corporation
20.6 DexTech Medical
20.7 Immune Pharmaceuticals
20.8 GlaxoSmithKline
20.9 Hospira
20.10 Insmed
20.11 Novartis
20.12 Pfizer
20.13 Roche
List of Figures:
Figure 1-1: Reasons for the Development of Cancer Cases (%)
Figure 1-2: Process Involved in the Metastasis of Cancer
Figure 1-3: Classes of Genes Participating in Metastatic Process in Cancer
Figure 2-1: Diagnostic Methods for Metastatic Lung Cancer
Figure 3-1: Diagnostic Approaches for Metastatic Bone Cancer
Figure 4-1: Metastatic Breast Cancer Diagnostic Methods
Figure 5-1: Metastatic Liver Cancer Diagnostic Methods
Figure 5-2: Treatment Approaches for Metastatic Liver Cancer
Figure 6-1: Diagnostic Approaches to Brain Tumor
Figure 6-2: Treatment Methods for Metastatic Brain Tumor
Figure 7-1: Diagnostic Approaches for Metastatic Prostate Cancer
Figure 7-2: Treatment Methods for Metastatic Prostate Cancer
Figure 9-1: Tarceva – Patent Approval & Expiration Year for Advance Stage Lung Cancer
Figure 9-2: Tarceva – Available Concentrations (mg), 2018
Figure 9-3: Tarceva – Dosage Analysis & Dose Modifications (mg/Day), 2018
Figure 9-4: Tarceva – Increased Dosage by Condition (mg/Day), 2018
Figure 9-5: Tarceva – Price Analysis by Concentration (US$), 2018
Figure 9-6: Tarceva – Therapy Cost Analysis (US$/Patient), 2018
Figure 9-7: Gefitinib – Drug Patent Approval Year & Expiration Year for Lung Cancer
Figure 9-8: Gefitinib – Clinical Efficacy by Patients Undergoing Treatment (%), 2018
Figure 9-9: Gefitinib – Dosage Analysis (mg), 2018
Figure 9-10: Gefitinib – Available Concentrations (mg), 2018
Figure 9-11: Gefitinib – Therapy Cost Analysis (US$/Patient), 2018
Figure 9-12: Afatinib – Patent Approval & Expiration Year for the Treatment of Lung Cancer
Figure 9-13: Afatinib - Available Concentrations (mg), 2018
Figure 9-14: Afatinib – Therapy Cost Analysis (US$), 2018
Figure 9-15 Cisplatin – Available Concentrations (ml), 2018
Figure 9-16: Cisplatin – Price Analysis by Concentration (US$), 2018
Figure 9-17: Topotecan - Patent Approval & Expiration Year
Figure 9-18: Topotecan – Available Concentration by Form (mg), 2018
Figure 9-19: Topotecan – Dosage Analysis by Route of Administration (mg/m2/Dose), 2018
Figure 9-20: Topotecan – Treatment Cycle Analysis (Number of Days), 2018
Figure 9-21: Topotecan – Dosage Analysis by Route of Administration (mg/Cycle), 2018
Figure 9-22: Topotecan – Capsule Price Analysis by Concentration (US$/Unit), 2018
Figure 9-23: Topotecan – Price Analysis by Drug Form (US$/Packet), 2018
Figure 9-24: Alimta Patent Approval & Expiration Year for Advanced Lung Cancer Treatment
Figure 9-25: Alimta - Available Concentration (mg), 2018
Figure 9-26: Alimta – Dosage Analysis (mg/Day), 2018
Figure 9-27: Alimta – Price Analysis by Concentration (US$), 2018
Figure 10-1: Patent Approval & Expiry Year of Denosumab Drug
Figure 10-2: Denosumab - Available Concentration & Dosage Analysis by Brand (mg/Day), 2018
Figure 10-3: Denosumab Comparative Cost Analysis – Xgeva v/s Prolia (US$/Unit)
Figure 10-4: Xofigo Patent Approval & Expiry Year
Figure 10-5: Xofigo – Therapy Cost Analysis (US$), 2018
Figure 10-6: Patent Approval Year & Expiry Year
Figure 10-7: Zometa – Available Concentrations (mg/ml), 2018
Figure 10-8: Zometa - Dosage & Treatment Cycle Duration Analysis (mg/Cycle), 2018
Figure 10-9: Zometa – Price Analysis (US$/Vial), 2018
Figure 11-1: Capecitabine - Available Concentrations (mg), 2018
Figure 11-2: Capecitabine – Dosage Analysis (mg/m2/Day), 2018
Figure 11-3: Capecitabine – Treatment Cycle Duration Analysis (Number of Weeks), 2018
Figure 11-4: Capecitabine & Xeloda - Comparative Cost Analysis by Concentration (US$/Packet), 2018
Figure 11-5: Eribulin Drug Patent Approval Year & Expiration Year for Metastatic Breast Cancer
Figure 11-6: Eribulin – Availability & Dosage Analysis (mg), 2018
Figure 11-7: Eribulin – Price Analysis (US$), 2018
Figure 11-8: Eribulin – Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-9: Ixabepilone Patent Approval & Expiry Year for Breast Cancer Treatment
Figure 11-10: Ixempra - Available Concentrations (MG), 2018
Figure 11-11: Ixempra – Dosage Analysis (mg/m2/Day), 2018
Figure 11-12: Ixempra – Price Analysis by Concentration (US$), 2018
Figure 11-13: Avastin Patent Approval & Expiration Year
Figure 11-14: Avastin – Available Concentrations (ml), 2018
Figure 11-15: Avastin – Average Dosage Analysis (mg/kg), 2018
Figure 11-16: Avastin – Price Analysis (US$), 2018
Figure 11-17: Avastin – Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-18: Herceptin - Available Concentrations (mg), 2018
Figure 11-19: Herceptin – Dosage Analysis (mg/kg), 2018
Figure 11-20: Herceptin – Price Analysis by Concentration (US$), 2018
Figure 12-1: Nexavar - Patent Approval & Expiry Year
Figure 12-2: Nexavar – Availability & Dosage Analysis (mg), 2018
Figure 12-3: Nexavar - Price Analysis (US$), 2018
Figure 12-4: Nexavar – Therapy Cost Analysis (US$/Patient), 2018
Figure 12-5: Alkeran - Drug Patent Approval & Expiration Year
Figure 12-6: Alkeran – Available Concentrations by Drug Form (mg), 2018
Figure 12-7: Alkeran – Treatment Cycle Analysis (By Number), 2018
Figure 12-8: Alkeran – Price Analysis by Drug Form (US$), 2018
Figure 13-1: Docetaxel - Available Concentrations (mg/ml), 2018
Figure 13-2: Docetaxel – Dosage Analysis (mg/m2/Dose), 2018
Figure 13-3: Docetaxel – Price Analysis (US$/Unit), 2018
Figure 13-4: Jevtana - Patent Approval & Expiry Year for Metastatic Prostate Cancer Treatment
Figure 13-5: Jevtana – Available Concentration & Dosage Analysis (mg), 2018
Figure 13-6: Jevtana – Price Analysis (US$), 2018
Figure 13-7: Patent Approval Years of Provenge Drug in US & Europe
Figure 13-8: Provenge – Number of Autologous CD54+ Activated Cells (Million)
Figure 13-9: Provenge – Dosage Administration (Minutes)
Figure 13-10: Provenge - Average Duration of Therapy
Figure 13-11: Provenge - Cost of Intravenous Solution & per Unit Cost, US$
Figure 13-12: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
Figure 13-13: Provenge – Average Cost (US$/Patient), 2018
Figure 13-14: Provenge – Therapy Cost Analysis (US$/Treatment Course), 2018
Figure 13-15: Overall Survival Rate among the Patients Using Provenge Drug (%)
Figure 14-1: Global – Metastatic Cancer Therapy Market Forecast (US$ Billion), 2017-2027
Figure 14-2: Global – Breast Cancer Therapeutics Forecast (US$ Billion), 2016-2026
Figure 14-3: Global - Prostate Cancer Therapeutics Market Forecast (US$ Billion), 2016-2027
Figure 14-4: Global – Tarceva Sales (US$ Million), 2015 – 2017
Figure 14-5: Global – Iressa Sales Analysis (US$ Million), 2015 - 2017
Figure 14-6: Global - Hycamtin Sales Analysis (US$ Million), 2015 & 2016
Figure 14-7: Global - Alimta Sales Analysis (US$ Million), 2015 – 2017*
Figure 14-8: Global - Prolia Sales Analysis (US$ Million), 2015 – 2017*
Figure 14-9: Global - Xofigo Sales Analysis (US$ Million), 2015 & 2017*
Figure 14-10: Global - Eribulin Sales Analysis (US$ Million), 2015 & 2016
Figure 14-11: Global - Avastin Sales Analysis (US$ Billion), 2015 – 2017*
Figure 14-12: Global – Herceptin Sales Analysis (US$ Billion), 2015 – 2017*
Figure 14-13: Global - Nexavar Sales Analysis (US$ Million), 2015 – 2017*
Figure 14-14: Global - Jevtana Sales Analysis (US$ Million), 2015 – 2017*
Figure 14-15: Global - Provenge Sales Analysis (US$ Million), 2015 & 2016
Figure 15-1: Favorable Parameters to Metastatic Cancer Market Growth
Figure 15-2: Challenges for the Development of Metastatic Cancer Treatment
Figure 17-1: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-2: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024
Figure 17-3: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-4: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024
List of Tables:
Table 3-1: Role of Tumor Secreted Factors in Establishment of Osteolytic & Osteoblastic Metastasis
Table 4-1: Organ Specific Breast Cancer Metastasis Progression & Virulence
Table 6-1: Modern Challenges & Solutions in Management of Brain Metastasis
Table 9-1: Patients Benefited by Using Afatinib Drug for Metastatic Lung Cancer
Table 9-2: Formulation & Preparation of Topotecan Drug, mg
Table 11-1: Clinical Efficacy of Using Eribulin for Metastatic Breast Cancer Treatment
Table 11-2: Clinical Efficacy of Using Ixempra for Metastatic Breast Cancer Treatment
Table 11-3: Clinical Efficacy Result of Avastin Drug with Paclitaxel drug
Table 11-4: Clinical Efficacy for the use of Herceptin Combined with Paclitaxel or Docetaxel